efficacy of oral amphotericin b for refractory atopic dermatitis with specific ige to candida albicans and food allergens in sera
Clicks: 361
ID: 186577
1997
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
361 views
42 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #16 of 108 articles by views in current drug discovery technologies
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The efficacy of oral amphotericin B (ApB) was studied in 125 cases of refractory atopic dermatitis (AD). Indications for ApB therapy were positive CAP-RAST (Pharmacia & Upjohn Co. Ltd)-class to Candida albicans and several food allergens and a high intake of sweets or alcoholic beverages together with recalcitrant symptoms of AD, such as facial erythema and eruptions refractory to topical steroids. Good or excellent results were obtained in 56.8% of 125 cases. Assessment of improvement in the 125 subjects was statistically compared with that in 55 controls who were not treated with ApB. There were no significant differences in the background between the two study groups. Cases treated with oral ApB showed significantly greater improvement (P <0.01) than did the controls, who were not treated with ApB, over 3 and 6 month periods. Treatment with ApB helped patients to discontinue or to reduce the frequency of topical steroid use or to change from high-dose steroids to lower-dose steroids. Treatment of patients with oral ApB resulted in improvements in laboratory data, including CAP-RAST to C. albicans and several food allergens. Good results were associated with restricting the intake of food allergens. A poor response was recognized in patients with a significantly high titer of CAP-RAST levels to Dermatophagoides farinae. Controlling environmental allergens and limiting exposure to food allergens was necessary to achieve success with ApB treatment.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (111 words).
Try re-searching for a better abstract.
| Reference Key |
kitamura1997allergologyefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Kazuko Kitamura;Chizuka Suga;Sumi Onuma;Toshiko Kawaguchi;Fusae Yamazaki;Hiroshi Suguro;Zenro Ikezawa |
| Journal | current drug discovery technologies |
| Year | 1997 |
| DOI |
10.2332/allergolint.46.125
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.